Association of PNPLA3 rs738409 C > G and rs2896019 T > G Polymorphisms with Nonalcoholic Fatty Liver Disease in a Turkish Population from Adıyaman Province.
{"title":"Association of <i>PNPLA3</i> rs738409 C > G and rs2896019 T > G Polymorphisms with Nonalcoholic Fatty Liver Disease in a Turkish Population from Adıyaman Province.","authors":"Süleyman Bayram, Yakup Ülger","doi":"10.1089/gtmb.2024.0481","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objectives:</i></b> The purpose of this study was to investigate the effect of patatin-like phospholipase domain-containing protein 3 (<i>PNPLA3</i>) rs738409 C > G and rs2896019 T > G polymorphisms on genetic susceptibility to nonalcoholic fatty liver disease (NAFLD) in a Turkish population from Adıyaman province, located in the Southeast Anatolia Region of Turkey. <b><i>Materials and Methods:</i></b> This hospital-based molecular epidemiological case-control study analyzed the <i>PNPLA3</i> rs738409 C > G and rs2896019 T > G polymorphisms in 335 NAFLD cases and 410 healthy controls. Genotype frequencies were determined using real-time polymerase chain reaction with the TaqMan assay. The association with NAFLD susceptibility was evaluated by calculating odds ratios (ORs) and 95% confidence intervals (CIs) using an unconditional logistic regression model. <b><i>Results:</i></b> We found that the <i>PNPLA3</i> rs738409 C > G (CC vs. GG: OR = 1.90, 95% CI = 1.05-3.44) and rs2896019 T > G (TT vs. GG: OR = 3.24, 95% CI = 1.44-7.27) polymorphisms were linked to an increased risk of NAFLD in almost all genetic models (<i>p</i> < 0.05). In addition, the <i>PNPLA3</i> Grs738409/Grs2896019 haplotype was associated with NAFLD development (<i>p</i> < 0.05). Significant differences in alanine aminotransferase and aspartate aminotransferase enzyme levels were observed across the genotypes of these polymorphisms (<i>p</i> < 0.05). <b><i>Conclusion:</i></b> This is the first study on <i>PNPLA3</i> single nucleotide polymorphisms (SNPs) and NAFLD in the Turkish population of Adıyaman Province, Southeast Anatolia. Our findings suggest that the <i>PNPLA3</i> rs738409 C > G and rs2896019 T > G polymorphisms, along with their haplotypes, may influence NAFLD susceptibility. Further independent studies with larger sample sizes and diverse populations are needed to confirm these results.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":"29 3","pages":"63-73"},"PeriodicalIF":1.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2024.0481","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: The purpose of this study was to investigate the effect of patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 C > G and rs2896019 T > G polymorphisms on genetic susceptibility to nonalcoholic fatty liver disease (NAFLD) in a Turkish population from Adıyaman province, located in the Southeast Anatolia Region of Turkey. Materials and Methods: This hospital-based molecular epidemiological case-control study analyzed the PNPLA3 rs738409 C > G and rs2896019 T > G polymorphisms in 335 NAFLD cases and 410 healthy controls. Genotype frequencies were determined using real-time polymerase chain reaction with the TaqMan assay. The association with NAFLD susceptibility was evaluated by calculating odds ratios (ORs) and 95% confidence intervals (CIs) using an unconditional logistic regression model. Results: We found that the PNPLA3 rs738409 C > G (CC vs. GG: OR = 1.90, 95% CI = 1.05-3.44) and rs2896019 T > G (TT vs. GG: OR = 3.24, 95% CI = 1.44-7.27) polymorphisms were linked to an increased risk of NAFLD in almost all genetic models (p < 0.05). In addition, the PNPLA3 Grs738409/Grs2896019 haplotype was associated with NAFLD development (p < 0.05). Significant differences in alanine aminotransferase and aspartate aminotransferase enzyme levels were observed across the genotypes of these polymorphisms (p < 0.05). Conclusion: This is the first study on PNPLA3 single nucleotide polymorphisms (SNPs) and NAFLD in the Turkish population of Adıyaman Province, Southeast Anatolia. Our findings suggest that the PNPLA3 rs738409 C > G and rs2896019 T > G polymorphisms, along with their haplotypes, may influence NAFLD susceptibility. Further independent studies with larger sample sizes and diverse populations are needed to confirm these results.
来自Adıyaman省土耳其人群的PNPLA3 rs738409 C > G和rs2896019 T > G多态性与非酒精性脂肪肝的关系
目的:本研究的目的是研究patatin样磷脂酶结构域蛋白3 (PNPLA3) rs738409 C b> G和rs2896019 T > G多态性对土耳其人群非酒精性脂肪性肝病(NAFLD)遗传易感性的影响,该人群位于土耳其东南安纳托利亚地区Adıyaman省。材料与方法:以医院为基础的分子流行病学病例对照研究,分析了335例NAFLD患者和410名健康对照者的PNPLA3 rs738409 C b> G和rs2896019 T > G多态性。采用TaqMan实时聚合酶链反应测定基因型频率。通过使用无条件逻辑回归模型计算比值比(ORs)和95%置信区间(CIs)来评估与NAFLD易感性的关联。结果:我们发现PNPLA3 rs738409 C > G (CC vs. GG: OR = 1.90, 95% CI = 1.05-3.44)和rs2896019 T > G (TT vs. GG: OR = 3.24, 95% CI = 1.44-7.27)多态性在几乎所有遗传模型中都与NAFLD风险增加有关(p < 0.05)。此外,PNPLA3 Grs738409/Grs2896019单倍型与NAFLD的发生相关(p < 0.05)。各基因型间谷丙转氨酶和天冬氨酸转氨酶水平差异显著(p < 0.05)。结论:本研究首次在东南安纳托利亚Adıyaman省土耳其人群中进行了PNPLA3单核苷酸多态性(snp)和NAFLD的研究。我们的研究结果表明,PNPLA3 rs738409 C > G和rs2896019 T > G多态性及其单倍型可能影响NAFLD的易感性。需要进一步进行更大样本量和不同人群的独立研究来证实这些结果。
期刊介绍:
Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results.
Genetic Testing and Molecular Biomarkers coverage includes:
-Diagnosis across the life span-
Risk assessment-
Carrier detection in individuals, couples, and populations-
Novel methods and new instrumentation for genetic testing-
Results of molecular, biochemical, and cytogenetic testing-
Genetic counseling